ADMA Biologics (ADMA) 10-Q 14 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 14, 2018
Document And Entity Information
Entity Registrant Name	ADMA BIOLOGICS, INC.
Entity Central Index Key	1,368,514
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		36,726,084
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,018

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current Assets
Cash and Cash Equivalents	$ 26,119,837	$ 43,107,574
Accounts Receivable	3,657,602	3,880,154
Inventories	12,438,802	12,628,181
Prepaid expenses and other current assets	2,703,214	2,050,740
Restricted cash	1,500,000	1,500,000
Total Current Assets	46,419,455	63,166,649
Property and equipment, net	30,615,530	30,466,858
Intangible assets, net	4,638,115	4,849,350
Goodwill	3,529,509	3,529,509
Assets to be transferred under purchase agreement	1,395,444	1,496,410
Restricted cash	4,000,000	4,000,000
Deposits	539,572	510,057
TOTAL ASSETS	91,137,625	108,018,833
Current Liabilities
Accounts Payable	5,718,121	5,920,873
Accrued Expenses	3,581,882	3,318,478
Current Portion of Deferred Revenue	142,834	142,834
Other current liabilities	0	57,998
Total Current Liabilities	9,442,837	9,440,183
Notes Payable, Net of Discount	25,616,653	25,368,458
End of Term Liability, Notes Payable	2,760,000	2,760,000
Deferred Revenue, Net of Current Portion	2,511,491	2,547,199
Note payable - related party, net of discount	14,850,048	14,842,396
Obligation to transfer assets under purchase agreement	12,621,844	12,621,844
Other non-current liabilities	309,353	105,996
TOTAL LIABILITIES	68,112,226	67,686,076
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock - voting, $0.0001 par value, 75,000,000 shares authorized, 36,726,084 and 36,725,499 shares issued and outstanding	3,673	3,673
Common Stock - non-voting, $0.0001 par value, 8,591,160 shares authorized, 8,591,160 shares issued and outstanding	859	859
Additional Paid-In Capital	191,536,802	191,022,018
Accumulated Deficit	(168,515,935)	(150,693,793)
TOTAL STOCKHOLDERS' EQUITY	23,025,399	40,332,757
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 91,137,625	$ 108,018,833

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Stockholders Equity
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, issued	36,726,084	36,725,499
Common stock, outstanding	36,726,084	36,725,499
Non-voting common stock, par value	$ .0001	$ 0.0001
Non-voting common stock, shares authorized	8,591,160	8,591,160
Non-voting common stock, issued	8,591,160	8,591,160
Non-voting common stock, outstanding	8,591,160	8,591,160

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
REVENUES:
Product revenue	$ 4,006,298	$ 2,593,163
License and other revenue	35,708	35,708
Total Revenues	4,042,006	2,628,871
OPERATING EXPENSES
Cost of product revenue (exclusive of amortization expense shown below)	12,242,748	1,616,287
Research and development	1,281,706	1,192,727
Plasma centers	1,833,774	1,479,476
Amortization of intangibles	211,235	0
Selling, general and administrative	5,005,046	4,277,384
TOTAL OPERATING EXPENSES	20,574,509	8,565,874
LOSS FROM OPERATIONS	(16,532,503)	(5,937,003)
OTHER INCOME (EXPENSE):
Interest income	26,546	18,568
Interest expense	(1,323,152)	(618,528)
Other income	6,967	0
OTHER EXPENSE, NET	(1,289,639)	(599,960)
NET LOSS	$ (17,822,142)	$ (6,536,963)
BASIC AND DILUTED LOSS PER COMMON SHARE	$ (0.39)	$ (0.51)
WEIGHTED AVERAGE SHARES OUTSTANDING, Basic and Diluted	45,317,042	12,886,741

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - 3 months ended Mar. 31, 2018 - USD ($)	Common Stock	Non-Voting Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2017	$ 3,673	$ 859	$ 191,022,018	$ (150,693,793)	$ 40,332,757
Beginning Balance, Shares at Dec. 31, 2017	36,725,499	8,591,160
Stock-based compensation			514,784		514,784
Stock options exercised, Shares	585
Net loss				(17,822,142)	(17,822,142)
Ending Balance, Amount at Mar. 31, 2018	$ 3,673	$ 859	$ 191,536,802	$ (168,515,935)	$ 23,025,399
Ending Balance, Shares at Mar. 31, 2018	36,726,084	8,591,160

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (17,822,142)	$ (6,536,963)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	829,541	118,062
Loss on disposal of fixed assets	0	(4,155)
Stock-based compensation	514,784	235,877
Amortization of debt discount	255,847	190,253
Amortization of license revenue	(35,708)	(35,708)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	222,552	178,089
Inventories	189,379	(288,346)
Prepaid expenses and other current assets	(652,474)	(432,932)
Other assets	(29,515)	(2,400)
Accounts payable	(202,754)	1,339,764
Accrued expenses	88,640	(160,637)
Other current and non-current liabilities	207,736	(7,640)
Net cash used in operating activities	(16,434,114)	(5,398,426)
CASH FLOWS FROM INVESTING ACTIVITIES:
Sales of short-term investments	0	5,145,184
Purchase of property and equipment	(549,246)	(3,584)
Net cash provided by (used in) investing activities	(549,246)	5,141,600
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on note payable	0	(1,111,111)
Payments of leasehold improvement loan	(4,377)	(4,002)
Net cash provided by financing activities	(4,377)	(1,115,113)
Net decrease in cash and cash equivalents	(16,987,737)	(1,371,939)
Cash and cash equivalents, including restricted cash - beginning of period	48,607,574	9,914,867
Cash and cash equivalents, including restricted cash - end of period	$ 31,619,837	$ 8,542,928

1. ORGANIZATION AND BUSINESS

1. ORGANIZATION AND BUSINESS	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
1. ORGANIZATION AND BUSINESS	ADMA Biologics, Inc. (“ADMA” or the “Company”) is a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of Primary Immune Deficiency Disease (“PIDD”) and the prevention and treatment of certain infectious diseases. The Company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (“ADMA BioManufacturing”) and ADMA Bio Centers Georgia Inc. (“ADMA BioCenters”). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of the Biotest Therapy Business Unit (“BTBU”) of Biotest Pharmaceuticals Corporation (“BPC” and, together with Biotest AG, “Biotest”) as more fully described below. ADMA BioCenters is the Company’s source plasma collection business, with facilities located in Norcross, GA, Marietta, GA and Kennesaw, GA. Both the Norcross and Marietta, GA facilities have approved licenses with the U.S. Food and Drug Administration (the “FDA”) and certifications from the German Health Authority (the “GHA”) and the Korean Ministry of Food and Drug Safety, and the Company filed a Biologics License Application (“BLA”) with the FDA for its Kennesaw, GA facility in December 2017 and, pending FDA approval, this facility is expected to be approved during the second half of 2018. ADMA BioCenters supplies ADMA with a portion of its raw material plasma for the manufacture of RI-002, ADMA’s lead pipeline product candidate, which the Company is currently developing for the treatment of PIDD. As discussed in Note 3, on June 6, 2017, ADMA completed the acquisition of certain assets (the “Biotest Assets”) of BTBU, which include two FDA-licensed products, Nabi-HB (Hepatitis B Immune Globulin, Human) and Bivigam (Immune Globulin Intravenous, Human), and a plasma fractionation facility located in Boca Raton, FL (the “Boca Facility”) (the “Biotest Transaction”). In addition to Nabi-HB and Bivigam, BTBU also provides contract manufacturing services for certain clients, including the sale of intermediate by-products. The Boca Facility is FDA-licensed and certified by the GHA. Immediately following the closing of the Biotest Transaction, the Biotest Assets were contributed into ADMA BioManufacturing. Nabi-HB is a hyperimmune globulin that is rich in antibodies to the hepatitis B virus. Nabi-HB is indicated for the treatment of acute exposure to blood containing hepatitis B surface antigen (“HBsAg”), prenatal exposure to infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute Hepatitis B virus infection. FDA approval for Nabi-HB was received on March 24, 1999. Under ADMA’s leadership, the production of Nabi-HB resumed during the third quarter of 2017, with subsequent commercial sales. Bivigam is indicated for the treatment of primary humoral immunodeficiency. FDA approval for Bivigam was received on December 19, 2012, and sales commenced in the first quarter of 2013. In December 2016, Biotest temporarily suspended the commercial production of Bivigam in order to focus on the completion of planned improvements to the manufacturing process. ADMA resumed production of Bivigam during the fourth quarter of 2017. The Bivigam inventory currently being produced will be used in conjunction with a Prior Approval Supplement (the “PAS”), which is expected to be filed with the FDA during the first half of 2018. Upon approval of the PAS by the FDA, the Company intends to relaunch Bivigam. This relaunch is expected to take place no earlier than the second half of 2018. Prior to the closing of the Biotest Transaction, BTBU was the Company’s third-party manufacturer for RI-002. In the third quarter of 2015, the FDA accepted for review the Company’s BLA for RI-002 (the “RI-002 BLA”) for the treatment of PIDD. In July 2016, the FDA issued a Complete Response Letter (the “CRL”) to the Company for the RI-002 BLA. Although the CRL did not cite any concerns with the clinical safety or efficacy data for RI-002 submitted in the RI-002 BLA, nor did the FDA request any additional clinical studies be completed prior to FDA approval of RI-002, the CRL reaffirmed the issues set forth in the November 2014 warning letter (the “Warning Letter”) that had been issued by the FDA to Biotest related to certain compliance issues identified at the Boca Facility, and also identified certain outstanding inspection issues and deficiencies at the Boca Facility and certain of the Company’s third-party vendors, and requested documentation of corrections for a number of these issues. The FDA indicated in the CRL that it cannot grant final approval of the BLA until, among other things, these deficiencies are resolved. Upon the completion of the Biotest Transaction, ADMA gained control over the regulatory, quality, general operations and drug substance manufacturing process at the Boca Facility, and the Company’s highest priority has been the remediation of the outstanding compliance issues that were identified at the Boca Facility in the Warning Letter. The Company has been working with a consulting firm consisting of quality management systems and biologics production subject matter experts in order to improve the FDA inspection classification relative to the Warning Letter compliance issues as indicated in the CRL. The Company anticipates that it will be in a position to refile the RI-002 BLA in the second half of 2018 and, pending FDA approval, ADMA anticipates initial commercial sales of RI-002 to occur no earlier than the first half of 2019. As of March 31, 2018, the Company had working capital of $37.0 million, including $26.1 million of cash and cash equivalents. Based upon the Company’s current projected revenue and expenditures for 2018, including capital expenditures and regulatory and consulting fees for the remediation of the Warning Letter and ongoing discussions with the FDA, as well as continuing implementation of the Company’s commercialization and expansion activities and certain other assumptions, the Company’s management currently believes that its cash, cash equivalents, projected revenue and accounts receivable, along with the $10.0 million it expects to be able to access under its senior credit facility, will be sufficient to fund ADMA’s operations, as currently conducted, into the fourth quarter of 2018. In order to have sufficient cash to fund its operations thereafter and to continue as a going concern, the Company will need to raise capital prior to the end of 2018. These estimates may change based upon how quickly the Company is able to execute on its quality management systems’ remediation plans for the ADMA BioManufacturing operations, timing of receipt of communications, determinations and feedback from the FDA regarding inspectional outcomes and remediation activities undertaken to date, commercial manufacturing ramp-up activities and the various financing options available to the Company. The Company currently has no firm commitments for additional financing, and there can be no assurances that the Company will be able to secure additional financing on terms that are acceptable to the Company, or at all. Furthermore, if the Company’s assumptions underlying its estimated expenses and revenues are incorrect, it may have to raise additional capital sooner than currently anticipated. Due to numerous risks and uncertainties associated with ongoing remediation efforts, the research and development and potential future commercialization of its products and product candidates, the Company is unable to estimate with certainty the amounts of increased capital outlays and operating expenditures associated with its development activities. The Company’s current estimates may be subject to change as circumstances regarding its business requirements evolve. The Company may decide to raise capital through public or private equity offerings or debt financings, or obtain a bank credit facility or corporate collaboration and licensing arrangements. The sale of additional equity or debt securities, if convertible, could result in dilution to the Company’s stockholders and, in such event, the value and potential future market price of its common stock may decline. The incurrence of indebtedness would result in increased fixed obligations and could also result in covenants that would restrict the Company’s operations or other financing alternatives. Failure to secure any necessary financing in a timely manner and on commercially reasonable terms could have a material adverse effect on the Company’s business plan and financial performance and it could be forced to delay or discontinue its product development, clinical trial or commercialization activities, delay or discontinue the approval efforts for any of the Company’s potential products or potentially cease operations. The Company has reported losses since inception in June 2004 through March 31, 2018 of $168.5 million. Management believes that the Company will continue to incur net losses and negative net cash flows from operating activities to fund its research and development, commercial programs and meet its obligations on a timely basis through the foreseeable future. As such, these factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of asset carrying amounts and the classification of liabilities that might be necessary from the outcome of this uncertainty.

2. SUMMARY OF SIGNIFICANT ACCOU

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (the “FASB”). The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 29, 2018. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in consolidated interim financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of March 31, 2018 and its results of operations for the three and ended March 31, 2018 and 2017 and cash flows for the three months ended March 31, 2018 and 2017. During the three months ended March 31, 2018 and 2017, comprehensive loss was equal to the net loss amounts presented for the respective periods in the accompanying condensed consolidated interim statements of operations. In addition, certain prior year balances have been reclassified to conform to the current presentation. Specifically, the change in the Company’s deferred rent liability in the accompanying statement of cash flows for the three months ended March 31, 2017 has been reclassified to changes in other current and non-current liabilities. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2018. Use of estimates The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the fair value of assets acquired and liabilities assumed in a business combination, the valuation of inventory and assumptions used in the fair value determination of stock-based compensation and the allowance for the valuation of future tax benefits. Business Combinations The Company accounts for business combinations using the acquisition method of accounting in accordance with FASB ASC 805, Business Combinations Fair value of financial instruments The carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company’s senior secured term loan (see Note 4) approximates fair value due to the variable interest rate on this debt. With respect to the related party note payable in the amount of $15.0 million as of March 31, 2018 (see Note 4), which is held by a principal stockholder of the Company and was issued concurrent with an acquisition transaction with such stockholder, the Company has concluded that an estimation of fair value for this note is not practicable. Accounts receivable Accounts receivable are reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are recognized in the period the related revenue is recorded. At March 31, 2018, three customers accounted for approximately 84% of the Company’s total accounts receivable, and at December 31, 2017, two customers accounted for approximately 79% of the Company’s total accounts receivable. Inventories Inventories, including plasma intended for resale and plasma intended for internal use in the Company's research and development and future anticipated commercialization activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Research and development plasma used in clinical trials is processed to a finished product and subsequently expensed to research and development. Although the Company expects that the Bivigam inventory produced during 2017 and 2018 will ultimately be available for commercial sale, due to uncertainties surrounding the timing and outcome of any FDA determinations concerning the Warning Letter and the PAS related to improvements in the manufacturing process that must be filed with and approved by the FDA prior to this inventory being available for commercial sale, all costs related to the production of Bivigam during the three months ended March 31, 2018 in the amount of $1.1 million have been charged to cost of product revenue in the accompanying consolidated statement of operations. In addition, the costs related to the manufacture of conformance lots of RI-002 during the three months ended March 31, 2018 in the amount of $2.5 million were also charged to cost of product revenue. Goodwill Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at March 31, 2018 and December 31, 2017 was $3.5 million. All of the Company’s goodwill is attributable to its ADMA BioManufacturing business segment. Goodwill is not amortized, but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the reporting unit’s carrying value exceeds its fair value, however the impairment loss recognized would not exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year. Impairment of long-lived assets The Company assesses the recoverability of its long-lived assets, which include property and equipment and definite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset’s value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the three months ended March 31, 2018 and 2017, the Company determined that there was no impairment of its long-lived assets. Revenue recognition Revenue from the sale of Nabi-HB is recognized when the product reaches the customer’s destination. Nabi-HB revenue is recorded net of estimated customer prompt pay discounts and contractual allowances in accordance with managed care agreements, including wholesaler chargebacks, rebates, customer returns and other wholesaler fees. For sales of intermediates, title typically transfers when the product is delivered to a third party warehouse. With all other contract manufacturing, the title transfers to the customer when they take possession of the product from the Boca Facility. As the Company maintains a significant risk of loss throughout the contract manufacturing process, contract manufacturing revenue is not recognized until the product is released and title transfers to the customer. Product revenues from the sale of human plasma collected at the Company’s plasma collection centers are recognized at the time of transfer of title and risk of loss to the customer, which generally occurs at the time of delivery. License and other revenues are primarily attributable to the out-licensing of RI-002 to Biotest to market and sell in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is recognized over the term of the Biotest license. Deferred revenue is amortized into income for a period of approximately 20 years, the term of the Biotest license agreement. For the three months ended March 31, 2018, three customers represented 90% of the Company’s consolidated revenues, with BPC representing 58% of the Company’s consolidated revenues and the other two customers representing 32% of the Company’s consolidated revenues. For the three months ended March 31, 2017, sales to BPC represented 81% of the Company’s consolidated revenues, and another customer represented 17% of the Company’s consolidated revenues. Cost of product revenue Cost of product revenue includes expenses related to process development as well as scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses. Expenses associated with remediating the issues identified in the Warning Letter for the three months ended March 31, 2018 in the approximate amount of $0.7 million are expensed as incurred and are reflected in cost of product revenue in the accompanying consolidated statements of operations. In addition, for the three months ended March 31, 2018, all operating expenses associated with the Boca Facility, other than the Nabi-HB production that was capitalized into inventory, have been expensed as incurred. Loss per common share Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. For purposes of computing basic and diluted loss per share, the non-voting class of common stock (see Notes 3 and 5) is included in the common stock outstanding as the characteristics of the non-voting class are substantially the same as the voting class of common stock. Diluted net loss per share is calculated by dividing net loss attributable to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock, including the non-voting class of common stock, and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants (using the treasury stock method). Potentially dilutive common stock in the diluted net loss per share computation is excluded to the extent that it would be anti-dilutive. No potentially dilutive securities are included in the computation of any diluted per share amounts as the Company reported a net loss for all periods presented. For the three months ended March 31, 2018 and 2017, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects: For the Three Months Ended March 31, 2018 2017 Stock options 4,127,950 1,691,123 Warrants 528,160 188,859 4,656,110 1,879,982 Stock-based compensation The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock options, to be recognized in the statements of operations as compensation expense based on their fair values at the date of grant. The Company uses the Black-Scholes option pricing model to determine the fair value of options granted. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term (see Note 5). During the three months ended March 31, 2018 and 2017, the Company granted stock options to purchase 848,700 and 182,000 shares of common stock, respectively, to its directors and employees, and during the three months ended March 31, 2018, the Company granted stock options to purchase 20,000 shares of common stock to a third party service provider. Recent Accounting Pronouncements In May 2017, the FASB issued ASU No. 2017-09, Modification Accounting for Share-Based Payment Arrangements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), In May 2014, the FASB issued new guidance related to revenue recognition, ASU 2014-09, Revenue from Contracts with Customers In March 2016, April 2016 and December 2016, the FASB issued ASU No. 2016-08, Revenue From Contracts with Customers (ASC 606): Principal Versus Agent Considerations Revenue From Contracts with Customers (ASC 606): Identifying Performance Obligations and Licensing Technical Corrections and Improvements to Topic 606, Revenue From Contracts with Customers Revenue from Contracts with Customers ADMA adopted the new standard and related updates effective January 1, 2018, using the modified retrospective method of adoption. Adoption of the new revenue recognition guidance did not have a material impact on the Company’s consolidated financial statements.

3. ACQUISITION

3. ACQUISITION	3 Months Ended
	Mar. 31, 2018
Acquisition
3. ACQUISITION	On June 6, 2017, ADMA completed the acquisition of the Biotest Assets from BPC. As a result of this transaction, the Company acquired Nabi-HB, Bivigam, the Boca Facility and certain other assets of BTBU. The acquisition of the Biotest Assets expands the Company’s product offering with two FDA-approved products and provides direct control over the manufacturing and regulatory processes impacting the Company’s RI-002 product candidate, including remediation of the Warning Letter as well as certain other remediation items affecting the Boca Facility. Pursuant to the acquisition, the Company issued to Biotest 4,295,580 voting shares of its common stock and 8,591,160 non-voting shares of common stock. The Company will also transfer ownership of two of its plasma centers to Biotest on January 1, 2019 as additional consideration, which are reflected as non-current assets in the accompanying consolidated balance sheets at March 31, 2018 and December 31, 2017 in the amount of $1.4 million and $1.5 million, respectively. As a result of the foregoing transaction, BPC became a principal stockholder and Biotest became a related party of the Company. Therefore, all transactions with Biotest subsequent to June 6, 2017, including product and license revenues attributable to Biotest (see Note 2), are related party transactions. The results from BTBU’s operations are included in the Company’s consolidated financial statements from the date of acquisition. The following unaudited pro forma summary presents consolidated information of the Company as if the business combination had occurred on January 1, 2017. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved had the acquisition been consummated as of that time or that may result in the future. Three Months Ended March 31, 2017 Revenues: As reported $ 2,628,871 Proforma $ 13,722,649 Net loss As reported $ (6,536,963 ) Proforma $ (12,773,860 ) Basic and diluted net loss per share: As reported $ (0.51 ) Proforma $ (0.50 )

4. DEBT

4. DEBT	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
4. DEBT	Senior Notes Payable A summary of outstanding senior notes payable is as follows: March 31, 2018 December 31, 2017 Notes payable: $ 30,000,000 $ 30,000,000 Less: Debt discount (4,383,347 ) (4,631,542 ) Senior notes payable $ 25,616,653 $ 25,368,458 On October 10, 2017 (the “Marathon Closing Date”), the Company entered into a Credit Agreement (the “Credit Agreement”) with Marathon Healthcare Finance Fund, L.P. (“Marathon” or the “Lender”) and Wilmington Trust, National Association, as the administrative agent for the Lender (the “Administrative Agent”). The Credit Agreement provides for a senior secured term loan facility in an aggregate amount of up to $40.0 million (collectively, the “Credit Facility”), comprised of (i) a term loan made on the Marathon Closing Date in the principal amount of $30.0 million evidenced by a secured promissory note (the “Tranche One Note”), and (ii) an additional term loan evidenced by a secured promissory note to be made in the maximum principal amount not to exceed $10.0 million (the “Tranche Two Note” and, together with the Tranche One Note, the “Notes”), which Tranche Two Note availability is subject to the satisfaction of certain conditions, including, but not limited to, those described below. The Notes each have a maturity date of April 10, 2022 (the “Maturity Date”), subject to acceleration pursuant to the Credit Agreement, including upon an Event of Default (as defined in the Credit Agreement). Borrowings under the Credit Agreement bear interest at a rate per annum equal to LIBOR plus 9.50% with a 1% LIBOR floor; provided, however, that in the event that the Company achieves sales of not less than $61.7 million for the 2018 calendar year and the Tranche Two Loan has been funded, then the interest rate on the borrowings under the Credit Agreement will decrease to LIBOR plus 7.75% with a 1% LIBOR floor. During an Event of Default under the Credit Agreement, the outstanding amount of indebtedness under the Credit Agreement will bear interest at a rate per annum equal to the interest rate then applicable to the borrowings under the Credit Agreement plus 5% per annum. Quarterly cash interest payments are due the first business day of each March, June, September and December, beginning on December 1, 2017. During the three months ended March 31, 2018, the interest rate on the Tranche One Note ranged from 10.99% to 11.51%. The Company will pay Marathon a facility fee in an amount equal to 9.20% of the amount of the Tranche One Note, payment of which is deferred until the Maturity Date pursuant to the terms of the Credit Agreement. Commencing on October 10, 2020, and on the first business day of each month, the Company is required to make principal payments on the Tranche One Note (and Tranche Two Note in the event it shall have been funded) in equal monthly installments over 18 months, subject to certain conditions in the Credit Agreement. The outstanding principal amount of the Notes, together with all accrued interest thereon, is due on the Maturity Date. The Credit Agreement contains market representations and warranties, affirmative covenants, negative covenants, financial covenants, and conditions that are customarily required for similar financings. The affirmative covenants, among other things, require the Company to undertake various reporting requirements. The negative covenants restrict or limit the ability of the Company and its subsidiaries to, among other things, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes or changes to the Company’s business activities; sell or otherwise dispose of assets; repurchase stock, pay dividends; repay certain other indebtedness; engage in certain affiliate transactions; or enter into any other agreements that restrict the Company’s ability to make loan repayments. In addition, the Company is required to maintain a minimum liquidity, defined in the Credit Agreement as cash held in the debt service reserve account and any other deposit account subject to a control agreement with the Administrative Agent, of not less than $5.5 million at all times. The Credit Agreement also required the establishment of the debt service reserve account. The Company is currently required to maintain a minimum balance in this account of $5.5 million, and this amount is reflected as restricted cash in the accompanying consolidated balance sheets as of March 31, 2018 and December 31, 2017. Upon the satisfaction of certain conditions related to some of the Company’s leased properties, the minimum required balance in the debt service reserve account, as well as the minimum liquidity requirement, will be reduced to $4.0 million. At March 31, 2018 and December 31, 2017, the Company was in compliance with all of the covenants contained in its senior lending agreements. The Credit Agreement also contains customary Events of Default which include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. The occurrence of an Event of Default could result in, among other things, the termination of commitments under the Credit Facility and the declaration that all outstanding Loans are immediately due and payable in whole or in part. Related Party Note Payable A summary of the outstanding related party note payable is as follows: March 31, 2018 December 31, 2017 Biotest - Gross proceeds $ 15,000,000 $ 15,000,000 Less: Debt discount (149,952 ) (157,604 ) Note payable - related party $ 14,850,048 $ 14,842,396 In connection with the acquisition of the Biotest Assets (see Note 3), ADMA BioManufacturing issued a subordinated note payable to BPC and in connection therewith received cash proceeds of $15.0 million. The note bears interest at a rate of 6.0% per annum and matures on June 6, 2022. The Company is obligated to make semi-annual interest payments, with all principal and unpaid interest due at maturity. The note is subordinate to all amounts outstanding under the Credit Agreement. In the event of default, all principal and unpaid interest is due on demand. The subordinated note also contains several non-financial covenants with which the Company was in compliance as of March 31, 2018. The Company incurred $0.2 million of debt issuance costs in connection with the issuance of this note, which were recorded as a debt discount. The debt discount is being amortized as interest expense over the term of the note.

5. STOCKHOLDERS_ EQUITY

5. STOCKHOLDERS’ EQUITY	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
5. STOCKHOLDERS’ EQUITY	Preferred Stock The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par value per share. There were no shares of preferred stock outstanding at March 31, 2018 and December 31, 2017. Common Stock As of March 31, 2018 and December 31, 2017, the Company was authorized to issue 75,000,000 shares of its common stock, and 36,726,084 and 36,725,499 shares of common stock, respectively, were outstanding. After giving effect to shares reserved for the issuance of warrants and stock options, 33,617,806 shares of common stock were available for issuance as of March 31, 2018. As of March 31, 2018 and December 31, 2017, 8,591,160 shares of the Company’s non-voting common stock were authorized, issued and outstanding. Equity Incentive Plan The fair value of stock options granted under the Company’s 2007 Employee Stock Option Plan (the “2007 Plan”) and the ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan, as amended and restated (the “2014 Plan”), was determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. The following assumptions were used to determine the fair value of options granted during the three months ended March 31, 2018 and 2017: Three Months Ended March 31, 2018 2017 Expected term 6.3 years 5.8 - 6.3 years Volatility 57% 64% Dividend yield 0.0 0.0 Risk-free interest rate 2.59% 2.29% The weighted average remaining contractual life of stock options outstanding and expected to vest at March 31, 2018 is 8.1 years. The weighted average remaining contractual life of stock options exercisable at March 31, 2018 is 5.8 years. A summary of the Company’s option activity under the 2007 Plan and 2014 Plan and related information is as follows: Three Months Ended March 31, 2018 Shares Weighted Average Exercise Price Outstanding at beginning of period 3,276,043 $ 5.52 Forfeited (12,500 ) $ 3.58 Expired (2,334 ) $ 2.68 Granted 868,700 $ 3.72 Exercised (1,959 ) $ 2.68 Outstanding at end of period and expected to vest 4,127,950 $ 5.15 Options exercisable 1,452,273 $ 7.51 During the three months ended March 31, 2018, an aggregate of 1,959 option shares were exercised in cashless exercise transactions resulting in the issuance of an aggregate of 585 shares of common stock. Stock-based compensation expense for the three months ended March 31, 2018 and 2017 is as follows: Three Months Ended March 31, 2018 2017 Research and development $ 78,305 $ 52,983 Plasma centers 7,086 12,751 Selling, general and administrative 394,858 170,143 Cost of product revenue 34,535 — Total stock-based compensation expense $ 514,784 $ 235,877 As of March 31, 2018, the Company had $5.3 million of unrecognized compensation expense related to options granted under the Company’s equity incentive plans, which is expected to be recognized over a weighted-average period of 3.0 years.

6. INVENTORIES

6. INVENTORIES	3 Months Ended
	Mar. 31, 2018
Inventories Abstract
6. INVENTORIES	The following table provides the components of inventories: March 31, 2018 December 31, 2017 Raw materials $ 8,962,207 $ 10,395,433 Work-in-progress 1,265,586 1,265,339 Finished goods 2,211,009 967,409 Total inventories $ 12,438,802 $ 12,628,181 Inventories are stated at the lower of cost or net realizable value with cost being determined on the first-in, first-out method. Finished goods inventories as of March 31, 2018 is comprised of Nabi-HB, a portion of which is recorded at fair value as part of the purchase price allocation of the Biotest Assets acquired. Raw materials includes materials expected to be used in the production of Nabi-HB, Bivigam and RI-002. All other activities and materials associated with the production of inventories used in research and development activities are expensed as incurred.

7. INTANGIBLE ASSETS

7. INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2018
Intangible Assets
7. INTANGIBLE ASSETS	Intangible assets at March 31, 2018 and December 31, 2017 consist of the following: March 31, 2018 December 31, 2017 Accumulated Accumulated Cost Amortization Net Cost Amortization Net Trademark and other intangible rights related to Nabi-HB $ 4,100,046 $ 488,101 $ 3,611,945 $ 4,100,046 $ 341,670 $ 3,758,376 Rights to intermediates 907,421 108,026 799,395 907,421 75,618 831,803 Customer contract 1,076,557 849,782 226,775 1,076,557 817,386 259,171 $ 6,084,024 $ 1,445,909 $ 4,638,115 $ 6,084,024 $ 1,234,674 4,849,350 All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets for the three months ended March 31, 2018 was $0.2 million. Estimated aggregate future aggregate amortization expense for the next five years is expected to be as follows: Remainder of 2018 $ 633,704 2019 715,352 2020 715,352 2021 715,352 2022 715,352

8. PROPERTY AND EQUIPMENT

8. PROPERTY AND EQUIPMENT	3 Months Ended
	Mar. 31, 2018
Property And Equipment
8. PROPERTY AND EQUIPMENT	Property, plant and equipment and related accumulated depreciation are summarized as follows: March 31, 2018 December 31, 2017 Manufacturing and laboratory equipment $ 7,148,405 $ 7,148,405 Office equipment and computer software 1,660,926 1,086,756 Furniture and fixtures 843,123 1,136,623 Construction in process 1,116,309 738,093 Leasehold improvements 1,650,029 1,642,903 Land 4,339,441 4,339,441 Buildings 15,660,559 15,660,559 32,418,792 31,752,780 Less: Accumulated depreciation and amortization (1,803,262 ) (1,285,922 ) $ 30,615,530 $ 30,466,858 Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset’s estimated useful life. Land is not depreciated. The buildings were assigned a useful life of 30 years. Property and equipment other than land and buildings have useful lives ranging from 3 to 10 years. Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives. The Company recorded depreciation expense on property and equipment of $0.6 million, which includes $0.1 million of depreciation expense on the plasma assets to be transferred (see Note 3), and $0.1 million for the three months ended March 31, 2018 and 2017, respectively.

9. RELATED PARTY TRANSACTIONS

9. RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2018
Related Party Transactions [Abstract]
9. RELATED PARTY TRANSACTIONS	The Company leases an office building and equipment from Areth, LLC (“Areth”) pursuant to a shared services agreement on a month-to-month basis of which terms had been amended by the Company’s Board of Directors in June 2016. Effective October 1, 2017, monthly rent on this facility was reduced to $10,000. Rent expense amounted to $30,000 and $48,000 for the three months ended March 31, 2018 and 2017, respectively. Areth is a company controlled by Dr. Jerrold B. Grossman, the Company’s Vice Chairman, and Adam S. Grossman, the Company’s President and Chief Executive Officer. The Company pays Areth monthly fees for the use of such office space and for other information technology, general warehousing and administrative services. The Company also reimburses Areth for office and building related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the three months ended March 31, 2018 and 2017. As part of the Biotest Transaction, the Company issued a $15.0 million subordinated note payable to BPC (see Note 4), and recognized interest expense on this note for the three months ended March 31, 2018 in the amount of $0.2 million. For the three months ended March 31, 2018 and 2017, the Company recognized revenues under its out-licensing agreement with Biotest of approximately $36,000. Deferred revenue of $2.7 million as of March 31, 2018 and December 31, 2017 is related to this agreement. Biotest is the Company’s largest customer for the sale of normal source plasma. Plasma sales to Biotest for the three months ended March 31, 2018 and 2017 were $2.3 million and $2.1 million, respectively. Accounts receivable includes $0.7 million and $1.2 million due from Biotest as of March 31, 2018 and December 31, 2017, respectively. Additionally, Biotest is a supplier of plasma to ADMA, with the Company purchasing $0.7 million and $0.2 million of plasma in the three months ended March 31, 2018 and 2017, respectively. Included in accounts payable is $0.1 million due to Biotest as of March 31, 2018 and December 31, 2017. The following table summarizes the related party balances with Biotest: Three Months Ended March 31, 2018 2017 Sale and purchase of plasma Product revenue $ 2,328,291 $ 2,092,215 Purchases 195,018 182,386 License revenue 35,708 35,708 Interest expense 225,000 — March 31, December 31, 2018 2017 Accounts receivable $ 726,409 $ 1,245,677 Prepaid expenses and other current assets 133,356 — Accounts payable 94,256 139,939 Accrued expenses 380,607 314,820 Note payable, net of discount 14,850,048 14,842,396 Accrued interest 290,000 65,000 Deferred revenue 2,654,325 2,690,033 In connection with the acquisition of the Biotest Assets, the Company entered into a Transition Services Agreement with BPC pursuant to which each of the Company and BPC agreed to provide transition services to the other party, including services related to finance, human resources, information technologies, leasing of equipment and clinical and regulatory services for a period of up to 24 months after the June 6, 2017 closing date, as well as agreements to lease certain laboratory space within the Boca Facility to BPC for a period of up to 24 months after the closing date of the acquisition transaction. As of March 31, 2018 and December 31, 2017, $0.4 million and $0.3 million, respectively, was payable by the Company to BPC for services rendered and expenses incurred on behalf of the Company related to these agreements. This amount is reflected in accrued expenses in the accompanying consolidated balance sheets. Under the terms of the acquisition of the Biotest Assets, the Company will transfer ownership of two plasma collection centers to BPC on January 1, 2019. The Company has estimated the fair value of these assets to be $12.6 million, and the obligation to transfer these assets to Biotest is reflected in non-current liabilities in the accompanying consolidated balance sheet as of March 31, 2018 and December 31, 2017. The services component of amounts billed to the Company by BPC for the three months ended March 31, 2018 was not material to the Company’s consolidated financial statements.

10. COMMITMENT AND CONTINGENCIE

10. COMMITMENT AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
10. COMMITMENT AND CONTINGENCIES	General Legal Matters From time to time the Company is or may become subject to certain legal proceedings and claims arising in connection with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company’s liquidity, results of operations or financial condition. Contract manufacturing agreement In connection with the acquisition of the Biotest Assets, the Company acquired all of the rights and assumed all of the obligations under an existing agreement with a third party related to the fractionation of plasma provided by the third party. This contract, as amended from time to time, maintains minimum production requirements as well as a payment due to the counterparty to the contract of $1.5 million per year if the minimum volume is not manufactured in that year and no other breach or default under the contract has occurred. Post-marketing commitments In connection with the approval of the BLA for Bivigam, on December 19, 2012 Biotest committed to perform two additional post-marketing studies, a pediatric study to evaluate the efficacy and safety of Bivigam in children and adolescents, and a post-authorization safety study to further assess the potential risk of hypotension and hepatic and renal impairment in Bivigam-treated patients with primary humoral immunodeficiency. These studies are still pending completion, ADMA has assumed the remaining obligations, and the costs of the studies will be expensed as incurred as research and development expenses. The Company currently expects both studies to be completed by the end of 2021. However, the timing of the completion of these studies is dependent upon the availability of Bivigam and the completion of the planned manufacturing process improvements. Other commitments In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company’s request in such capacities. The Company’s maximum exposure under these arrangements is unknown as of March 31, 2018. The Company does not anticipate recognizing any significant losses relating to these arrangements.

11. SEGMENTS

11. SEGMENTS	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
11. SEGMENTS	The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company’s operating segments reflect the consummation of the Biotest Transaction on June 6, 2017 (see Notes 1 and 3), and the nature of its operations subsequent to the close of the transaction. The Company’s ADMA BioManufacturing segment reflects the Company’s immune globulin manufacturing and development operations in Florida, acquired on June 6, 2017 (see Note 3). The Plasma Collection Centers segment consists of two FDA-licensed source plasma collection facilities located in Georgia, with a third collection center which opened in December 2017 and for which an FDA license in pending. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables: Three Months Ended March 31, 2018 ADMA BioManufacturing Plasma Collection Centers Corporate Consolidated Revenues $ 1,666,243 $ 2,340,055 $ 35,708 $ 4,042,006 Cost of product revenue 10,697,642 1,545,106 — 12,242,748 Loss from operations (12,724,718 ) (1,038,824 ) (2,768,961 ) (16,532,503 ) Other expense, net (240,054 ) (435 ) (1,049,150 ) (1,289,639 ) Net loss (12,964,772 ) (1,039,259 ) (3,818,111 ) (17,822,142 ) Total assets 47,481,781 27,532,613 16,123,231 91,137,625 Depreciation and amortization expense 631,832 188,914 8,795 829,541 Capital expenditures 105,199 444,047 — 549,246 Three Months Ended March 31, 2017 ADMA BioManufacturing Plasma Collection Centers Corporate Consolidated Revenues $ — $ 2,593,163 $ 35,708 $ 2,628,871 Cost of product revenue — 1,616,287 — 1,616,287 Loss from operations — (502,600 ) (5,434,403 ) (5,937,003 ) Other expense, net — — (599,960 ) (599,960 ) Net loss — (502,600 ) (6,034,363 ) (6,536,963 ) Total assets — 2,286,500 15,308,418 17,594,918 Depreciation and amortization expense — 103,640 14,422 118,062 Capital expenditures — 2,084 1,500 3,584

12. SUPPLEMENTAL DISCLOSURE OF

12. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	3 Months Ended
	Mar. 31, 2018
Supplemental Disclosure Of Cash Flow Information
12. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	Supplemental cash flow information for the three months ended March 31, 2018 and 2017 is as follows: 2018 2017 SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest $ 825,513 $ 424,470 Noncash Financing and Investing Activities: Equipment acquired reflected in accounts payable and accrued liabilities $ 116,766 $ —

13. SUBSEQUENT EVENTS

13. SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
13. SUBSEQUENT EVENTS	On May 14, 2018, the Company, ADMA BioManufacturing and ADMA BioCenters entered into a Share Transfer, Amendment and Release Agreement with BPC, Biotest AG, Biotest US Corporation and The Biotest Divestiture Trust (the “Biotest Trust”) (the “Biotest Transfer Agreement”) whereby BPC transferred to the Company, for no cash consideration, 8,591,160 shares of the Company’s non-voting common stock previously issued to BPC in connection with the Biotest Transaction and representing 100% of the Company’s issued and outstanding non-voting common stock (the “NV Biotest Shares”). Immediately upon transfer of the NV Biotest Shares to the Company, the shares were retired and are no longer available for issuance. The retired NV Biotest Shares comprised approximately 19% of the total outstanding common stock of the Company as of May 14, 2018. In exchange for the transfer and retirement of the NV Biotest Shares, the Company has (i) granted Biotest and its successors and assigns a release from all potential past, present and future indemnity claims arising under the Master Purchase and Sale Agreement, dated as of January 21, 2017, and (ii) relinquished its rights to repurchase its two FDA-approved plasma collection centers required to be transferred to BPC on January 1, 2019 (see Note 3). In addition, pursuant to the Biotest Transfer Agreement, BPC waived and terminated its rights to name a director and an observer to the Company’s Board of Directors. As BPC has made public statements regarding the U.S. Government required divestiture of all of BPC’s U.S. assets in connection with the sale of Biotest AG to CREAT Group Corporation, pursuant to the Biotest Transfer Agreement BPC, subject to the receipt of required regulatory approvals, has agreed to transfer its remaining 10,109,534 shares of the Company’s common stock to the Biotest Trust upon the earlier of (i) receipt of consent from the necessary governmental authorities and (ii) July 1, 2018 (provided that Biotest and the Biotest Trust have received all required regulatory approvals for the Biotest Trust to own and hold the Company’s common stock) (the “Voting Share Closing Date”). Furthermore, pursuant to the Biotest Transfer Agreement, the Biotest Trust has agreed to be bound by all obligations of, and will have all of the remaining rights of, BPC under that certain (i) Stockholders Agreement, dated as of June 6, 2017, by and between the Company and BPC, as amended by the Biotest Transfer Agreement, and (ii) Registration Rights Agreement, dated as of June 6, 2017, by and between the Company and BPC. Furthermore, subject to the terms contained in the Biotest Transfer Agreement, for a 90-day period following the Voting Share Closing Date, the Biotest Trust has granted the Company a right of first negotiation for the purchase of the remaining shares of common stock then-held by the Biotest Trust.

2. SUMMARY OF SIGNIFICANT ACC20

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of presentation	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (the “FASB”). The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 29, 2018. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in consolidated interim financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of March 31, 2018 and its results of operations for the three and ended March 31, 2018 and 2017 and cash flows for the three months ended March 31, 2018 and 2017. During the three months ended March 31, 2018 and 2017, comprehensive loss was equal to the net loss amounts presented for the respective periods in the accompanying condensed consolidated interim statements of operations. In addition, certain prior year balances have been reclassified to conform to the current presentation. Specifically, the change in the Company’s deferred rent liability in the accompanying statement of cash flows for the three months ended March 31, 2017 has been reclassified to changes in other current and non-current liabilities. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2018.
Use of estimates	The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the fair value of assets acquired and liabilities assumed in a business combination, the valuation of inventory and assumptions used in the fair value determination of stock-based compensation and the allowance for the valuation of future tax benefits.
Business Combinations	The Company accounts for business combinations using the acquisition method of accounting in accordance with FASB ASC 805, Business Combinations
Fair value of financial instruments	The carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company’s senior secured term loan (see Note 4) approximates fair value due to the variable interest rate on this debt. With respect to the related party note payable in the amount of $15.0 million as of March 31, 2018 (see Note 4), which is held by a principal stockholder of the Company and was issued concurrent with an acquisition transaction with such stockholder, the Company has concluded that an estimation of fair value for this note is not practicable.
Accounts receivable	Accounts receivable are reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are recognized in the period the related revenue is recorded. At March 31, 2018, three customers accounted for approximately 84% of the Company’s total accounts receivable, and at December 31, 2017, two customers accounted for approximately 79% of the Company’s total accounts receivable.
Inventories	Inventories, including plasma intended for resale and plasma intended for internal use in the Company's research and development and future anticipated commercialization activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Research and development plasma used in clinical trials is processed to a finished product and subsequently expensed to research and development. Although the Company expects that the Bivigam inventory produced during 2017 and 2018 will ultimately be available for commercial sale, due to uncertainties surrounding the timing and outcome of any FDA determinations concerning the Warning Letter and the PAS related to improvements in the manufacturing process that must be filed with and approved by the FDA prior to this inventory being available for commercial sale, all costs related to the production of Bivigam during the three months ended March 31, 2018 in the amount of $1.1 million have been charged to cost of product revenue in the accompanying consolidated statement of operations. In addition, the costs related to the manufacture of conformance lots of RI-002 during the three months ended March 31, 2018 in the amount of $2.5 million were also charged to cost of product revenue.
Goodwill	Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at March 31, 2018 and December 31, 2017 was $3.5 million. All of the Company’s goodwill is attributable to its ADMA BioManufacturing business segment. Goodwill is not amortized, but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the reporting unit’s carrying value exceeds its fair value, however the impairment loss recognized would not exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year.
Impairment of long-lived assets	The Company assesses the recoverability of its long-lived assets, which include property and equipment and definite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset’s value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the three months ended March 31, 2018 and 2017, the Company determined that there was no impairment of its long-lived assets.
Revenue recognition	Revenue from the sale of Nabi-HB is recognized when the product reaches the customer’s destination. Nabi-HB revenue is recorded net of estimated customer prompt pay discounts and contractual allowances in accordance with managed care agreements, including wholesaler chargebacks, rebates, customer returns and other wholesaler fees. For sales of intermediates, title typically transfers when the product is delivered to a third party warehouse. With all other contract manufacturing, the title transfers to the customer when they take possession of the product from the Boca Facility. As the Company maintains a significant risk of loss throughout the contract manufacturing process, contract manufacturing revenue is not recognized until the product is released and title transfers to the customer. Product revenues from the sale of human plasma collected at the Company’s plasma collection centers are recognized at the time of transfer of title and risk of loss to the customer, which generally occurs at the time of delivery. License and other revenues are primarily attributable to the out-licensing of RI-002 to Biotest to market and sell in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is recognized over the term of the Biotest license. Deferred revenue is amortized into income for a period of approximately 20 years, the term of the Biotest license agreement. For the three months ended March 31, 2018, three customers represented 90% of the Company’s consolidated revenues, with BPC representing 58% of the Company’s consolidated revenues and the other two customers representing 32% of the Company’s consolidated revenues. For the three months ended March 31, 2017, sales to BPC represented 81% of the Company’s consolidated revenues, and another customer represented 17% of the Company’s consolidated revenues.
Cost of product revenue	Cost of product revenue includes expenses related to process development as well as scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses. Expenses associated with remediating the issues identified in the Warning Letter for the three months ended March 31, 2018 in the approximate amount of $0.7 million are expensed as incurred and are reflected in cost of product revenue in the accompanying consolidated statements of operations.
Loss per common share	Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. For purposes of computing basic and diluted loss per share, the non-voting class of common stock (see Notes 3 and 5) is included in the common stock outstanding as the characteristics of the non-voting class are substantially the same as the voting class of common stock. Diluted net loss per share is calculated by dividing net loss attributable to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock, including the non-voting class of common stock, and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants (using the treasury stock method). Potentially dilutive common stock in the diluted net loss per share computation is excluded to the extent that it would be anti-dilutive. No potentially dilutive securities are included in the computation of any diluted per share amounts as the Company reported a net loss for all periods presented. For the three months ended March 31, 2018 and 2017, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects: For the Three Months Ended March 31, 2018 2017 Stock options 4,127,950 1,691,123 Warrants 528,160 188,859 4,656,110 1,879,982
Stock-based compensation	The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock options, to be recognized in the statements of operations as compensation expense based on their fair values at the date of grant. The Company uses the Black-Scholes option pricing model to determine the fair value of options granted. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term (see Note 5). During the three months ended March 31, 2018 and 2017, the Company granted stock options to purchase 848,700 and 182,000 shares of common stock, respectively, to its directors and employees, and during the three months ended March 31, 2018, the Company granted stock options to purchase 20,000 shares of common stock to a third party service provider.
Recent Accounting Pronouncements	In May 2017, the FASB issued ASU No. 2017-09, Modification Accounting for Share-Based Payment Arrangements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), In May 2014, the FASB issued new guidance related to revenue recognition, ASU 2014-09, Revenue from Contracts with Customers In March 2016, April 2016 and December 2016, the FASB issued ASU No. 2016-08, Revenue From Contracts with Customers (ASC 606): Principal Versus Agent Considerations Revenue From Contracts with Customers (ASC 606): Identifying Performance Obligations and Licensing Technical Corrections and Improvements to Topic 606, Revenue From Contracts with Customers Revenue from Contracts with Customers ADMA adopted the new standard and related updates effective January 1, 2018, using the modified retrospective method of adoption. Adoption of the new revenue recognition guidance did not have a material impact on the Company’s consolidated financial statements.

2. SUMMARY OF SIGNIFICANT ACC21

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2018
Summary Of Significant Accounting Policies Tables
Schedule of dilutive securities	For the Three Months Ended March 31, 2018 2017 Stock options 4,127,950 1,691,123 Warrants 528,160 188,859 4,656,110 1,879,982

3. ACQUISITION (Tables)

3. ACQUISITION (Tables)	3 Months Ended
	Mar. 31, 2018
Acquisition Tables
Pro forma information	Three Months Ended March 31, 2017 Revenues: As reported $ 2,628,871 Proforma $ 13,722,649 Net loss As reported $ (6,536,963 ) Proforma $ (12,773,860 ) Basic and diluted net loss per share: As reported $ (0.51 ) Proforma $ (0.50 )

4. DEBT (Tables)

4. DEBT (Tables) - Oxford Loan	3 Months Ended
	Mar. 31, 2018
Summary of notes payable	March 31, 2018 December 31, 2017 Notes payable: $ 30,000,000 $ 30,000,000 Less: Debt discount (4,383,347 ) (4,631,542 ) Senior notes payable $ 25,616,653 $ 25,368,458
Summary of related party notes payable	March 31, 2018 December 31, 2017 Biotest - Gross proceeds $ 15,000,000 $ 15,000,000 Less: Debt discount (149,952 ) (157,604 ) Note payable - related party $ 14,850,048 $ 14,842,396

5. STOCKHOLDERS_ EQUITY (Tables

5. STOCKHOLDERS’ EQUITY (Tables)	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Schedule of assumptions	Three Months Ended March 31, 2018 2017 Expected term 6.3 years 5.8 - 6.3 years Volatility 57% 64% Dividend yield 0.0 0.0 Risk-free interest rate 2.59% 2.29%
Schedule of stock option activity	Three Months Ended March 31, 2018 Shares Weighted Average Exercise Price Outstanding at beginning of period 3,276,043 $ 5.52 Forfeited (12,500 ) $ 3.58 Expired (2,334 ) $ 2.68 Granted 868,700 $ 3.72 Exercised (1,959 ) $ 2.68 Outstanding at end of period and expected to vest 4,127,950 $ 5.15 Options exercisable 1,452,273 $ 7.51
Stock-based compensation expense	Three Months Ended March 31, 2018 2017 Research and development $ 78,305 $ 52,983 Plasma centers 7,086 12,751 Selling, general and administrative 394,858 170,143 Cost of product revenue 34,535 — Total stock-based compensation expense $ 514,784 $ 235,877

6. INVENTORIES (Tables)

6. INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2018
Inventories Tables
Schedule of inventory	March 31, 2018 December 31, 2017 Raw materials $ 8,962,207 $ 10,395,433 Work-in-progress 1,265,586 1,265,339 Finished goods 2,211,009 967,409 Total inventories $ 12,438,802 $ 12,628,181

7. INTANGIBLE ASSETS (Tables)

7. INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2018
Intangible Assets Tables
Schedule of intangible assets	March 31, 2018 December 31, 2017 Accumulated Accumulated Cost Amortization Net Cost Amortization Net Trademark and other intangible rights related to Nabi-HB $ 4,100,046 $ 488,101 $ 3,611,945 $ 4,100,046 $ 341,670 $ 3,758,376 Rights to intermediates 907,421 108,026 799,395 907,421 75,618 831,803 Customer contract 1,076,557 849,782 226,775 1,076,557 817,386 259,171 $ 6,084,024 $ 1,445,909 $ 4,638,115 $ 6,084,024 $ 1,234,674 4,849,350
Intangible asset future aggregate amortization expense	Remainder of 2018 $ 633,704 2019 715,352 2020 715,352 2021 715,352 2022 715,352

8. PROPERTY AND EQUIPMENT (Tabl

8. PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2018
Property And Equipment Tables
Schedule of property and equipment	March 31, 2018 December 31, 2017 Manufacturing and laboratory equipment $ 7,148,405 $ 7,148,405 Office equipment and computer software 1,660,926 1,086,756 Furniture and fixtures 843,123 1,136,623 Construction in process 1,116,309 738,093 Leasehold improvements 1,650,029 1,642,903 Land 4,339,441 4,339,441 Buildings 15,660,559 15,660,559 32,418,792 31,752,780 Less: Accumulated depreciation and amortization (1,803,262 ) (1,285,922 ) $ 30,615,530 $ 30,466,858

9. RELATED PARTY TRANSACTIONS (

9. RELATED PARTY TRANSACTIONS (Tables)	3 Months Ended
	Mar. 31, 2018
Related Party Transactions Tables
Schedule of related party transactions	Three Months Ended March 31, 2018 2017 Sale and purchase of plasma Product revenue $ 2,328,291 $ 2,092,215 Purchases 195,018 182,386 License revenue 35,708 35,708 Interest expense 225,000 — March 31, December 31, 2018 2017 Accounts receivable $ 726,409 $ 1,245,677 Prepaid expenses and other current assets 133,356 — Accounts payable 94,256 139,939 Accrued expenses 380,607 314,820 Note payable, net of discount 14,850,048 14,842,396 Accrued interest 290,000 65,000 Deferred revenue 2,654,325 2,690,033

11. SEGMENTS (Tables)

11. SEGMENTS (Tables)	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Summarized segment financial information	Three Months Ended March 31, 2018 ADMA BioManufacturing Plasma Collection Centers Corporate Consolidated Revenues $ 1,666,243 $ 2,340,055 $ 35,708 $ 4,042,006 Cost of product revenue 10,697,642 1,545,106 — 12,242,748 Loss from operations (12,724,718 ) (1,038,824 ) (2,768,961 ) (16,532,503 ) Other expense, net (240,054 ) (435 ) (1,049,150 ) (1,289,639 ) Net loss (12,964,772 ) (1,039,259 ) (3,818,111 ) (17,822,142 ) Total assets 47,481,781 27,532,613 16,123,231 91,137,625 Depreciation and amortization expense 631,832 188,914 8,795 829,541 Capital expenditures 105,199 444,047 — 549,246 Three Months Ended March 31, 2017 ADMA BioManufacturing Plasma Collection Centers Corporate Consolidated Revenues $ — $ 2,593,163 $ 35,708 $ 2,628,871 Cost of product revenue — 1,616,287 — 1,616,287 Loss from operations — (502,600 ) (5,434,403 ) (5,937,003 ) Other expense, net — — (599,960 ) (599,960 ) Net loss — (502,600 ) (6,034,363 ) (6,536,963 ) Total assets — 2,286,500 15,308,418 17,594,918 Depreciation and amortization expense — 103,640 14,422 118,062 Capital expenditures — 2,084 1,500 3,584

12. SUPPLEMENTAL DISCLOSURE O30

12. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2018
Supplemental Disclosure Of Cash Flow Information Tables
Schedule of supplemental cash flow information	2018 2017 SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest $ 825,513 $ 424,470 Noncash Financing and Investing Activities: Equipment acquired reflected in accounts payable and accrued liabilities $ 116,766 $ —

1. ORGANIZATION AND BUSINESS (D

1. ORGANIZATION AND BUSINESS (Details Narrative) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cash and cash equivalents	$ 26,119,837	$ 43,107,574
Accumulated deficit	$ (168,515,935)	$ (150,693,793)

2. SUMMARY OF SIGNIFICANT ACC32

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Potentially dilutive securities	4,656,110	1,879,982
Stock Options
Potentially dilutive securities	4,127,950	1,691,123
Warrants
Potentially dilutive securities	528,160	188,859

2. SUMMARY OF SIGNIFICANT ACC33

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Summary Of Significant Accounting Policies Details Narrative
Options issued to employees and directors	848,700	182,000

3. ACQUISITION (Details)

3. ACQUISITION (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues:
As reported	$ 4,042,006	$ 2,628,871
Net loss
As reported	$ (17,822,142)	(6,536,963)
Proforma		$ (12,773,860)
Basic and diluted net loss per share:
As reported	$ (0.39)	$ (0.51)
Proforma		$ (0.50)

4. DEBT (Details)

4. DEBT (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Debt Details
Net Proceeds	$ 30,000,000	$ 30,000,000
Less:
Debt discount	(4,383,347)	(4,631,542)
Notes Payable	$ 25,616,653	$ 25,368,458

4. DEBT (Details 1)

4. DEBT (Details 1) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Debt Details 1
Biotest - Gross proceeds	$ 15,000,000	$ 15,000,000
Less:
Debt discount	(149,952)	(157,604)
Note payable - related party	$ 14,850,048	$ 14,842,396

5. STOCKHOLDERS_ EQUITY (DEFICI

5. STOCKHOLDERS’ EQUITY (DEFICIT) (Details)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
STOCKHOLDERS' EQUITY
Expected Term	6 years 3 months 18 days
Expected Term, minimum		5 years 9 months 18 days
Expected Term, maximum		6 years 3 months 18 days
Volatility	57.00%	64.00%
Dividend yield	0.00%	0.00%
Risk-free interest rate	2.59%	2.29%

5. STOCKHOLDERS' EQUITY (DEFICI

5. STOCKHOLDERS' EQUITY (DEFICIT) (Details 1)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Shares
Outstanding at beginning of period | shares	3,276,043
Forfeited | shares	(12,500)
Expired | shares	(2,334)
Granted | shares	868,700
Exercised | shares	(1,959)
Outstanding at end of period and expected to vest | shares	4,127,950
Options exercisable | shares	1,452,273
Weighted Average Exercise Price
Outstanding at beginning of period | $ / shares	$ 5.52
Forfeited | $ / shares	3.58
Expired | $ / shares	2.68
Granted | $ / shares	3.72
Exercised | $ / shares	2.68
Outstanding at end of period and expected to vest | $ / shares	5.15
Options exercisable | $ / shares	$ 7.51

5. STOCKHOLDERS' EQUITY (DEFI39

5. STOCKHOLDERS' EQUITY (DEFICIT) (Details 2) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Total stock-based compensation expense	$ 514,784	$ 235,877
Research and development
Total stock-based compensation expense	78,305	52,983
Plasma centers
Total stock-based compensation expense	7,086	12,751
Selling, general and administrative
Total stock-based compensation expense	394,858	170,143
Cost of goods sold
Total stock-based compensation expense	$ 34,535	$ 0

6. INVENTORIES (Details)

6. INVENTORIES (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Inventories Details
Raw materials	$ 8,962,207	$ 10,395,433
Work-in-progress	1,265,586	1,265,339
Finished goods	2,211,009	967,409
Total inventories	$ 12,438,802	$ 12,628,181

7. INTANGIBLE ASSETS (Details)

7. INTANGIBLE ASSETS (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Cost	$ 6,084,024	$ 6,084,024
Accumulated Amortization	1,445,909	1,234,674
Net	4,638,115	4,849,350
Trademark and other intangible rights related to Nabi-HB®
Cost	4,100,046	4,100,046
Accumulated Amortization	488,101	341,670
Net	3,611,945	3,758,376
Right to intermediates
Cost	907,421	907,421
Accumulated Amortization	108,026	75,618
Net	799,395	831,803
Customer contract
Cost	1,076,557	1,076,557
Accumulated Amortization	849,782	817,386
Net	$ 226,775	$ 259,171

7. INTANGIBLE ASSETS (Details 1

7. INTANGIBLE ASSETS (Details 1)	Mar. 31, 2018USD ($)
Intangible Assets Details 1
Remainder of 2018	$ 633,704
2,019	715,352
2,020	715,352
2,021	715,352
2,022	$ 715,352

8. PROPERTY AND EQUIPMENT (Deta

8. PROPERTY AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Property, plant and equipments, gross	$ 32,418,792	$ 31,752,780
Less: Accumulated depreciation and amortization	(1,803,262)	(1,285,922)
Property, plant and equipments, net	30,615,530	30,466,858
Manufacturing and laboratory equipment
Property, plant and equipments, gross	7,148,405	7,148,405
Office equipment and computer software
Property, plant and equipments, gross	1,660,926	1,086,756
Furniture and fixtures
Property, plant and equipments, gross	843,123	1,136,623
Construction in process
Property, plant and equipments, gross	1,116,309	738,093
Leasehold improvements
Property, plant and equipments, gross	1,650,029	1,642,903
Land
Property, plant and equipments, gross	4,339,441	4,339,441
Buildings
Property, plant and equipments, gross	$ 15,660,559	$ 15,660,559

9. RELATED PARTY TRANSACTIONS44

9. RELATED PARTY TRANSACTIONS (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Sale and purchase of plasma
Product revenue	$ 2,328,291	$ 2,092,215
Purchases	195,018	182,386
License revenue	35,708	35,708
Interest expense	225,000	$ 0
Accounts receivable	726,409		$ 1,245,677
Prepaid expenses and other current assets	133,356		0
Accounts payable	94,256		139,939
Accrued expenses	380,607		314,820
Note payable, net of discount	14,850,048		14,842,396
Accrued interest	290,000		65,000
Deferred revenue	$ 2,654,325		$ 2,690,033

11. SEGMENTS (Details)

11. SEGMENTS (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues	$ 4,042,006	$ 2,628,871
Cost of product revenue	12,242,748	1,616,287
Loss from operations	(16,532,503)	(5,937,003)
Other expense, net	(1,289,639)	(599,960)
Net loss	(17,822,142)	(6,536,963)
Total assets	91,137,625	17,594,918
Depreciation and amortization expense	829,541	118,062
Capital expenditures	829,541	3,584
ADMA BioManufacturing
Revenues	1,666,243	0
Cost of product revenue	10,697,642	0
Loss from operations	(12,724,718)	0
Other expense, net	(240,054)	0
Net loss	(12,964,772)	0
Total assets	47,481,781	0
Depreciation and amortization expense	105,199	0
Capital expenditures	631,832	0
Plasma Collection Center Member
Revenues	2,340,055	2,593,163
Cost of product revenue	1,545,106	1,616,287
Loss from operations	(1,038,824)	(502,600)
Other expense, net	(435)	0
Net loss	(1,039,259)	(502,600)
Total assets	27,532,613	2,286,500
Depreciation and amortization expense	444,047	103,640
Capital expenditures	188,914	2,084
Corporate Member
Revenues	35,708	35,708
Cost of product revenue	0	0
Loss from operations	(2,768,961)	(5,434,403)
Other expense, net	(1,049,150)	(599,960)
Net loss	(3,818,111)	(6,034,363)
Total assets	16,123,231	15,308,418
Depreciation and amortization expense	0	14,422
Capital expenditures	$ 8,795	$ 1,500

12. SUPPLEMENTAL DISCLOSURE O46

12. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
SUPPLEMENTAL INFORMATION:
Cash paid for interest	$ 825,513	$ 424,470
Noncash Financing and Inesting Activities:
Equipment acquired reflected in accounts payable and accrued liabilities	$ 116,766	$ 0